You just read:

Janssen Announces Results Of Two Phase 3 Studies Which Showed Long-Acting Injectable HIV Treatment Regimen Of Rilpivirine And Cabotegravir Demonstrated Comparable Safety And Efficacy To Daily Oral HIV Therapy

News provided by

Janssen Pharmaceutical Companies of Johnson & Johnson

Mar 07, 2019, 13:45 ET